---
title: "Zhejiang Medicine: Plans to repurchase company shares for 100 million to 200 million yuan, with a repurchase price not exceeding 20.83 yuan per share"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236542922.md"
description: "On April 18th, ZMC announced that it plans to repurchase company shares through centralized bidding, with a total repurchase amount of no less than RMB 100 million and no more than RMB 200 million. The repurchase price will not exceed RMB 20.83 per share. The repurchased shares will be used for employee stock ownership plans or equity incentives. The repurchase period is within 12 months from the date the board of directors approves the share repurchase plan"
datetime: "2025-04-18T08:34:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236542922.md)
  - [en](https://longbridge.com/en/news/236542922.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236542922.md)
---

# Zhejiang Medicine: Plans to repurchase company shares for 100 million to 200 million yuan, with a repurchase price not exceeding 20.83 yuan per share

On April 18th, ZMC announced that it plans to repurchase company shares through centralized bidding, with a total repurchase amount of no less than RMB 100 million and no more than RMB 200 million. The repurchase price will not exceed RMB 20.83 per share. The repurchased shares will be used for employee stock ownership plans or equity incentives. The repurchase period is within 12 months from the date the board of directors approves the share repurchase plan

### Related Stocks

- [600216.CN](https://longbridge.com/en/quote/600216.CN.md)

## Related News & Research

- [Analysis-as US debt mounts, investors demand higher returns to lend](https://longbridge.com/en/news/296213098.md)
- [REG - American Century Inv Spire Healthcare Grp - Form 8.3 - Spire Healthcare Group PLC](https://longbridge.com/en/news/296117308.md)
- [What hike? Why Wall Street is abandoning its call for higher rates.](https://longbridge.com/en/news/296128417.md)
- [LEO outlays $435m for rights to Tanabe’s rare disease drug for sun-induced pain](https://longbridge.com/en/news/296217400.md)
- [CanSinoBIO's NDA for Td5cp Adolescent and Adult Accepted, Further Strengthening Its Diversified Vaccine Pipeline](https://longbridge.com/en/news/296024108.md)